Examination of Factors Affecting the Association of PCSK9 With Low-Density Lipoprotein Particles in Human Plasma

被引：0
|
作者：
Golder, Mia
Sarkar, Samantha
Kosenko, Tanja
McPherson, Ruth
Lagace, Thomas A.
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A433
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity
    Guijarro, Carlos
    JAMA CARDIOLOGY, 2017, 2 (10) : 1168 - +
  • [22] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):
  • [23] A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels
    Tremblay, Frederic
    Xiong, Qiang
    Shah, Shrijal S.
    Ko, Chih-Wei
    Kelly, Kenneth
    Morrison, Mary S.
    Giancarlo, Cristiana
    Ramirez, Ricardo N.
    Hildebrand, Erica M.
    Voytek, Sarah B.
    El Sebae, Gabriel K.
    Wright, Shane H.
    Lofgren, Liam
    Clarkson, Scott
    Waters, Christine
    Linder, Samantha J.
    Liu, Songlei
    Eom, Taesun
    Parikh, Shefal
    Weber, Yuki
    Martinez, Salette
    Malyala, Padma
    Abubucker, Sahar
    Friedland, Ari E.
    Maeder, Morgan L.
    Lombardo, Angelo
    Myer, Vic E.
    Jaffe, Aron B.
    NATURE MEDICINE, 2025, : 1329 - 1338
  • [24] Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
    Kosenko, Tanja
    Golder, Mia
    Leblond, Geoffrey
    Weng, Willy
    Lagace, Thomas A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (12) : 8279 - 8288
  • [25] A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol
    Fasano, Tommaso
    Cefalu, Angelo B.
    Di Leo, Enza
    Noto, Davide
    Pollaccia, Daniela
    Bocchi, Letizia
    Valenti, Vincenza
    Bonardi, Renato
    Guardamagna, Ornella
    Averna, Maurizio
    Tarugi, Patrizia
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (03) : 677 - 681
  • [26] Both Rare and Common Variants in PCSK9 Influence Plasma Low-Density Lipoprotein Cholesterol Level in American Indians
    Tsai, Ching-Wei
    North, Kari E.
    Tin, Adrienne
    Haack, Karin
    Franceschini, Nora
    Voruganti, V. Saroja
    Laston, Sandy
    Zhang, Ying
    Best, Lyle G.
    MacCluer, Jean W.
    Beaty, Terri H.
    Navas-Acien, Ana
    Kao, W. H. Linda
    Howard, Barbara V.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (02): : E345 - E349
  • [27] Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables
    Filippatos, Theodosios D.
    Kei, Anastazia
    Rizos, Christos V.
    Elisaf, Moses S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (01) : 3 - 12
  • [28] Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
    Duff, Christopher J.
    Scottt, Martin J.
    Kirby, Ian T.
    Hutchinson, Sue E.
    Martin, Steve L.
    Hooper, Nigel M.
    BIOCHEMICAL JOURNAL, 2009, 419 : 577 - 584
  • [29] PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity Reply
    Koren, Michael J.
    Sabatine, Marc S.
    JAMA CARDIOLOGY, 2017, 2 (10) : 1169 - 1169
  • [30] Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein (LDL) Receptor Suppression Mediated By PCSK9
    Melone, Michelle
    Rashid, Shirya
    OBESITY, 2011, 19 : S60 - S60
12345